---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001112"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T09:22:25.597147+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 restores lifespan to near-normal in preclinical progeria model

## Summary
- In C. elegans with wrn-1 mutation (Werner Syndrome model), Telomir-1 restored lifespan to near-normal levels.
- Progeria causes rapid aging in children; these results suggest potential for Telomir-1 to address cellular aging issues.
- Telomir Pharmaceuticals (Nasdaq: TELO) announced the findings in an SEC filing on Jan 7, 2025.

## SEC filing metadata
- accession: 0001493152-25-001112
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225001112/0001493152-25-001112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225001112/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001112
- JSON: https://secwatch.observer/filing/0001493152-25-001112.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.